Voclosporin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Voclosporin, a structurally similar analogue of cyclosporin A, is a new type of calcineurin inhibitor. It has been modified to increase its activity by 3-4 times and exhibits a dual and synergistic mechanism. This drug works by blocking the expression of IL-2 and T cell-mediated immune response, stabilizing renal podocytes. Compared to cyclosporin, voclosporin has the advantage of having less impact on cholesterol and triglycerides and a lower risk of diabetes. In February 2021, vorcyclosporine was approved by the FDA for use in combination immunosuppressive regimens in adult patients with active, lupus nephritis.
Definition
ChEBI: Voclosporin is a homodetic cyclic peptide. It is a semi-synthetic calcineurin (CN) inhibitor that exhibits potent immunosuppressive activity.
Indications
Voclosporin is approved by the USFDA for the treatment of active lupus nephritis.
Clinical Use
Voclosporin (Lupkynis(TM)) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis.
Einzelnachweise
1. Voclosporin: First Approval DOI:
10.1007/s40265-021-01488-z 2. Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis DOI:
10.1177/10600280221075331
Voclosporin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
